Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Evotec and Sernova partnered to develop an implantable induced pluripotent stem cell (iPSC)-based beta cell replacement therapy that can be used to treat both type 1 and 2 diabetes patients.
Researchers continue to explore how to turn deadly venom into life-saving drugs. Several papers on the subject have recently been published and BioSpace is taking a look at them.
During the past several years, data generation, data mining and analytics have progressed to the point that it is now possible to bring precision medicine to psychiatry.
Agios Pharmaceuticals is cutting its staff numbers by 50 as part of plans to lay low on exploratory research efforts to focus on the success of late-stage initiatives.
Cugene and AbbVie came together on autoimmune diseases and cancer, while Proteros and AstraZeneca expanded their collaboration on epigenetic cancer drugs.
In honor of ALS Awareness Month, BioSpace spoke with leading researchers like Dr. Matthew Harms of Columbia University and Drs. Howard Berman and Stanley Appel at Coya Therapeutics.
Sofinnova Partners announced on Monday that it entered into a long-term strategic and financial partnership with Apollo to expand its presence in the life sciences.
Orna announced first-ever data from its lead isCAR program that validates both the technology and its LNP delivery platform. BioSpace spoke with ORNA CEO Tom Barnes.
Sanofi, AstraZeneca, Avillion and Diadem recently announced clinical results, providing positive news for patients with multiple myeloma, asthma and Alzheimer’s disease.
The American Society of Gene & Cell Therapy (ASGCT) Annual Meeting kicked off Monday with multiple presentations highlighting the potential of new treatments for a myriad of diseases.
Orphazyme has several products with potential, with biopharma company KemPharm acquiring nearly all of the company’s assets and operations.
Akebia Therapeutics’s partner Otsuka Pharmaceutical Co. announced plans to terminate its global license agreements with Akebia for vadadustat.